Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neema Navai

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Oncotarget|August 6, 2016
Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasisBeat Roth, Isuru Jayaratna, Debasish Sundi, et al.
BJU International|September 6, 2017
Effects of thiazolidinedione in patients with active bladder cancerRoger Li, Michael J Metcalfe, James E Ferguson, et al.
European Urology Open Science|July 13, 2023
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival OutcomesWei Shen Tan, Valentina Grajales, Roberto Contieri, et al.
Journal of Endourology|July 22, 2017
Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term OutcomesMichael Metcalfe, Gavin Wagenheim, Lianchun Xiao, et al.
European Urology Oncology|May 3, 2021
Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy OutcomesPatrick J Hensley, Kelly K Bree, Nathan Brooks, et al.
Prostate Cancer and Prostatic Diseases|December 13, 2017
Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancerBrian F Chapin, Jenny N Nguyen, Mary F Achim, et al.
The Journal of Urology|June 30, 2022
All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta TumorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
BJU International|February 20, 2024
Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomyRoberto Contieri, Wei Shen Tan, Valentina Grajales, et al.
European Urology Oncology|July 19, 2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder CancerWei Shen Tan, Ian M McElree, Facundo Davaro, et al.
The Journal of Urology|June 30, 2022
Reply by AuthorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Oncotarget|August 6, 2016
Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasisBeat Roth, Isuru Jayaratna, Debasish Sundi, et al.
BJU International|September 6, 2017
Effects of thiazolidinedione in patients with active bladder cancerRoger Li, Michael J Metcalfe, James E Ferguson, et al.
European Urology Open Science|July 13, 2023
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival OutcomesWei Shen Tan, Valentina Grajales, Roberto Contieri, et al.
Journal of Endourology|July 22, 2017
Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term OutcomesMichael Metcalfe, Gavin Wagenheim, Lianchun Xiao, et al.
European Urology Oncology|May 3, 2021
Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy OutcomesPatrick J Hensley, Kelly K Bree, Nathan Brooks, et al.
Prostate Cancer and Prostatic Diseases|December 13, 2017
Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancerBrian F Chapin, Jenny N Nguyen, Mary F Achim, et al.
The Journal of Urology|June 30, 2022
All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta TumorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
BJU International|February 20, 2024
Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomyRoberto Contieri, Wei Shen Tan, Valentina Grajales, et al.
European Urology Oncology|July 19, 2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder CancerWei Shen Tan, Ian M McElree, Facundo Davaro, et al.
The Journal of Urology|June 30, 2022
Reply by AuthorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
Pageof 11